Allogene Therapeutics, Inc. Payments to Acquire Assets, Investing Activities
Allogene Therapeutics, Inc. (ALLO) reported Payments to Acquire Assets, Investing Activities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAssetsInvestingActivities · last filed 2021-02-25
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for the quarter ending 2019-12-31 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for the quarter ending 2019-09-30 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for the quarter ending 2018-12-31 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for the quarter ending 2018-09-30 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for fiscal 2020 was $0.00.
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Allogene Therapeutics, Inc. payments to acquire assets, investing activities for fiscal 2018 was $2.10M.
| Period end | Payments to Acquire Assets, Investing Activities 1 month | Payments to Acquire Assets, Investing Activities 3 month | Payments to Acquire Assets, Investing Activities 6 month | Payments to Acquire Assets, Investing Activities 9 month | Payments to Acquire Assets, Investing Activities 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $2.10M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $2.10M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $2.10M 10-Q · filed 2019-08-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |